Company: LNAI
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001731122-25-000765
Chunk: 119

Company: Lunai Bioworks Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 119
---
     (7,289,156) 
     18,279,156  
     (251)%
  
    Change in fair value of equity securities 
     210,281  
     —  
     210,281  
     100% 
     210,281  
     —  
     210,281  
     100%
  
    Loss on extinguishment of debt 
     —  
     —  
     —  
     —  
     —  
     (120,018) 
     120,018  
     (100)%
  
    Interest expense 
     (188,685) 
     (303,802) 
     115,117  
     (38)% 
     (537,656) 
     (758,057) 
     220,401  
     (29)%
  
    Interest and other income 
     72  
     (16,272) 
     16,344  
     (100)% 
     109,483  
     8,041  
     101,442  
     1,262%
  
    Total Other Income (Expense) 
     4,351,668  
     (7,609,230) 
     11,960,898  
     (157)% 
     10,772,108  
     (8,159,190) 
     18,931,298  
     (232)%
  
    NET INCOME (LOSS) 
    $189,176  
    $(58,990,070) 
    $59,179,246  
     100% 
    $(51,275,253) 
    $(72,694,219) 
    $21,418,966  
     (29)%

Revenues

We are a pre-revenue, pre-clinical
biotechnology and artificial intelligence driven healthcare technology company. We have never generated revenues and have incurred losses
since inception. We do not anticipate earning any revenue until our therapies or products are approved for marketing and sale.

33

Expenses 

Our operating expenses for the
three months ended March 31, 2025 and 2024, were $4,162,492 and $51,380,840 respectively, representing
a decrease